Deprescribing Overactive Bladder Medications for Parkinson's Disease

This trial aims to determine if individuals with Parkinson's disease can safely reduce or stop using medications for overactive bladder. Researchers will gradually lower the dose of these medications, known as antimuscarinics, to assess if symptoms remain manageable without them. The trial explores whether fewer medications could enhance life quality for those with Parkinson's. It suits individuals with Parkinson's who have taken these bladder medications for at least three months and can engage in online and phone activities. As a Phase 4 trial, the treatment has already received FDA approval and proven effective. This research seeks to understand its benefits for more patients, offering a unique opportunity to contribute to broader knowledge while potentially improving personal health outcomes.

Yes, you will need to gradually reduce and aim to stop your overactive bladder medication during certain periods of the trial. The trial involves reducing the dose by 25-50% every 1-2 weeks with the goal of completely discontinuing the medication.

Research has shown that antimuscarinic medications, commonly used to treat overactive bladder (OAB), may pose safety concerns, particularly for individuals with Parkinson's disease. Studies suggest these medications might increase the likelihood of requiring urgent medical care compared to other treatments. Evidence also indicates that these drugs can impair memory and thinking skills, potentially leading to cognitive decline.

Researchers are excited about deprescribing overactive bladder medications for Parkinson's disease because it explores a method to potentially reduce medication burden. Unlike the standard approach where antimuscarinic medications are maintained indefinitely, this method gradually tapers the dosage to find the lowest effective dose or to discontinue entirely. This approach could help minimize side effects while still managing symptoms, offering a personalized treatment strategy that balances efficacy with quality of life.

Research has shown that people with Parkinson's disease often experience bladder problems, known as overactive bladder (OAB). Antimuscarinic medications are commonly used to treat OAB symptoms, but they can cause side effects such as dry mouth and constipation. Studies indicate that these medications can alleviate symptoms like the urgent need to urinate and frequent urination, though issues like nocturia (needing to urinate at night) might still occur. However, limited information exists on the long-term safety of these drugs for people with Parkinson's. In this trial, participants will follow a single-arm AB(AB) sequence to evaluate whether reducing or stopping these medications might help without worsening symptoms.¹²³⁵⁶